Market Overview:
The global plasma protease C1-inhibitor treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of hereditary angioedema (HAE) and rising demand for plasma protease inhibitors for prophylaxis and treatment of HAE. Based on type, the global plasma protease inhibitor treatment market is segmented into C1-inhibitors and kallikrein inhibitors. The kallikrein inhibitors segment is expected to grow at a higher CAGR than the C1-inhibitors segment during the forecast period. This growth can be attributed to increasing awareness about kallikrein inhibitors as an effective therapy for HAE among patients and healthcare professionals. Based on application, the global plasma protease inhibitor treatment market is divided into hospital pharmacies, independent pharmacies, and retail outlets/clinics.
Product Definition:
Plasma protease C1-inhibitor is a treatment used to prevent the breakdown of blood clots. It is important because it helps to keep blood flowing smoothly and prevents the formation of dangerous clots.
C1-inhibitors:
C1-inhibitors are a group of drugs that decrease the activity of the first component (protease) in the blood clotting process. C1-inhibitors are used to treat conditions such as deep vein thrombosis, pulmonary embolism, and heart attack. The condition where there is too much protein in the blood known as hyperproteinementia can also be treated with C1-inhibitor medication.
Kallikrein Inhibitor (Kalbitor):
Kallikrein inhibitor (Kalbitor) is a drug that decreases the production of kallikrein, an enzyme responsible for producing protease-peptides. It works by blocking the action of kallikrein in blood vessels and causes dilation or widening of blood vessels. This increase in blood vessel size allows more fluid to flow through them which results in lowering of hypertension (high blood pressure).
Application Insights:
The market is segmented by application into hospital pharmacies, independent pharmacies and outlets, and others. Hospital pharmacies held the largest share in 2017 owing to factors such as high patient admissions in hospitals, which increases the demand for protease c1-inhibitors. The independent pharmacy/outlet segment is expected to witness lucrative growth over the forecast period due to increasing awareness about affordable drugs among consumers.
Plasma protease inhibitor treatments are most commonly prescribed for people with inflammatory bowel disease or Crohn¢â‚¬â„¢s disease who have not responded well to other medications or therapies.
Regional Analysis:
North America dominated the global plasma protease C1-inhibitor treatment market in 2017. The presence of a large number of players, high adoption rate for new technologies, and favorable reimbursement policies are some factors attributing to its large share. In addition, increasing incidence of chronic diseases such as cancer and HIV/AIDS is also expected to drive the demand for cost-effective drugs over the forecast period.
Asia Pacific is estimated to be fastest growing region during the forecast period owing to rising healthcare expenditure by governments and private sectors in countries such as China, India Japan & Korea (J&K), Singapore among others which has led to an increase in awareness about advanced treatments for various diseases along with availability of these treatments at lower costs compared with North America & Europe.
Growth Factors:
- Increasing incidence of hereditary angioedema (HAE)
- Growing awareness about HAE and its treatment options
- Rising demand for plasma protease C1-inhibitor therapy from emerging markets
- Technological advancements in the field of plasma protease C1-inhibitor therapy
- increasing number of clinical studies on the efficacy and safety of plasma protease C1-inhibitor therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasma Protease C1-inhibitor Treatment Market Research Report
By Type
C1-inhibitors, Kallikrein Inhibitor (Kalbitor)
By Application
Hospital Pharmacies, Independent Pharmacies and Outlets
By Companies
Takeda, CSL, Sanquin, Pharming Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
171
Number of Tables & Figures
120
Customization Available
Yes, the report can be customized as per your need.
Global Plasma Protease C1-inhibitor Treatment Market Report Segments:
The global Plasma Protease C1-inhibitor Treatment market is segmented on the basis of:
Types
C1-inhibitors, Kallikrein Inhibitor (Kalbitor)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Independent Pharmacies and Outlets
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- CSL
- Sanquin
- Pharming Group
Highlights of The Plasma Protease C1-inhibitor Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- C1-inhibitors
- Kallikrein Inhibitor (Kalbitor)
- By Application:
- Hospital Pharmacies
- Independent Pharmacies and Outlets
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasma Protease C1-inhibitor Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasma protease C1-inhibitor treatment is a type of medication used to treat certain types of blood clots. Plasma protease C1-inhibitors work by blocking the activity of plasma proteases, which can help to prevent blood clots from forming.
Some of the major players in the plasma protease c1-inhibitor treatment market are Takeda, CSL, Sanquin, Pharming Group.
The plasma protease c1-inhibitor treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasma Protease C1-inhibitor Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Plasma Protease C1-inhibitor Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Plasma Protease C1-inhibitor Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Plasma Protease C1-inhibitor Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Plasma Protease C1-inhibitor Treatment Market Size & Forecast, 2020-2028
4.5.1 Plasma Protease C1-inhibitor Treatment Market Size and Y-o-Y Growth
4.5.2 Plasma Protease C1-inhibitor Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 C1-inhibitors
5.2.2 Kallikrein Inhibitor (Kalbitor)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Independent Pharmacies and Outlets
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasma Protease C1-inhibitor Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 C1-inhibitors
9.6.2 Kallikrein Inhibitor (Kalbitor)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Independent Pharmacies and Outlets
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 C1-inhibitors
10.6.2 Kallikrein Inhibitor (Kalbitor)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Independent Pharmacies and Outlets
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 C1-inhibitors
11.6.2 Kallikrein Inhibitor (Kalbitor)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Independent Pharmacies and Outlets
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 C1-inhibitors
12.6.2 Kallikrein Inhibitor (Kalbitor)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Independent Pharmacies and Outlets
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 C1-inhibitors
13.6.2 Kallikrein Inhibitor (Kalbitor)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Independent Pharmacies and Outlets
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasma Protease C1-inhibitor Treatment Market: Competitive Dashboard
14.2 Global Plasma Protease C1-inhibitor Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 CSL
14.3.3 Sanquin
14.3.4 Pharming Group
